Prof Petrylak talks with ecancer at the Best of ASCO 2017 meeting in Miami about the early use of the CYP17A1 inhibitor, abiraterone, for patients with metastatic, hormone sensitive, prostate cancer. He goes on to discuss the data from, and the...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2uhE9Jc
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Caring for Patients with Physical Disabilities: Assessment of an Innovative Spinal Cord Injury Session that Addresses an Educational Gap Des...
-
Objective Outpatient parenteral antimicrobial therapy (OPAT) provides opportunities for improved cost savings, but in the UK, implementation...
-
Abstract Objective To study the effects of Astragalus polysaccharide (APS), the primary effective component of the Chinese herb medicine A...
-
Geriatric trauma: A population-based study Saint Shiou-Sheng Chen, Li-Chien Chien Formosan Journal of Surgery 2019 52(2):39-44 Background: G...
-
Abstract Eslicarbazepine acetate is a new anti-epileptic drug belonging to the dibenzazepine carboxamide family that is currently approved ...
-
Objectives Adult sagittal posture is established during childhood and adolescence. A flattened or hypercurved spine is associated with poore...
-
Related Articles Randomized clinical trial of percutaneous tibial nerve stimulation versus sham electrical stimulation in patients wit...
-
Abstract Objective To evaluate Chinese medicine (CM) formula Bazheng Powder (八正散) as an alternative therapeutic option for female patients...
-
Related Articles Disrupted relationship between "resting state" connectivity and task-evoked activity during social percepti...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου